446 related articles for article (PubMed ID: 25293776)
1. Curing myeloma at last: defining criteria and providing the evidence.
Barlogie B; Mitchell A; van Rhee F; Epstein J; Morgan GJ; Crowley J
Blood; 2014 Nov; 124(20):3043-51. PubMed ID: 25293776
[TBL] [Abstract][Full Text] [Related]
2. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Zangari M; van Rhee F; Anaissie E; Pineda-Roman M; Haessler J; Crowley J; Barlogie B
Br J Haematol; 2008 May; 141(4):433-44. PubMed ID: 18371114
[TBL] [Abstract][Full Text] [Related]
3. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Barlogie B; Tricot G; Rasmussen E; Anaissie E; van Rhee F; Zangari M; Fassas A; Hollmig K; Pineda-Roman M; Shaughnessy J; Epstein J; Crowley J
Blood; 2006 Apr; 107(7):2633-8. PubMed ID: 16322468
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Usmani SZ; Hoering A; Cavo M; Miguel JS; Goldschimdt H; Hajek R; Turesson I; Lahuerta JJ; Attal M; Barlogie B; Lee JH; Kumar S; Lenhoff S; Morgan G; Rajkumar SV; Durie BGM; Moreau P
Blood Cancer J; 2018 Nov; 8(12):123. PubMed ID: 30470751
[TBL] [Abstract][Full Text] [Related]
5. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
6. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
7. Complete response after autologous stem cell transplant in multiple myeloma.
Kumar L; Iqbal N; Mookerjee A; Verma RK; Sharma OD; Batra A; Pramanik R; Gupta R
Cancer Med; 2014 Aug; 3(4):939-46. PubMed ID: 24777883
[TBL] [Abstract][Full Text] [Related]
8. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
9. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
11. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
Usmani SZ; Crowley J; Hoering A; Mitchell A; Waheed S; Nair B; AlSayed Y; Vanrhee F; Barlogie B
Leukemia; 2013 Jan; 27(1):226-32. PubMed ID: 22705990
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
14. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
15. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Jethava YS; Mitchell A; Epstein J; Zangari M; Yaccoby S; Tian E; Waheed S; Khan R; Papanikolaou X; Grazziutti M; Cottler-Fox M; Petty N; Steward D; Panozzo S; Bailey C; Hoering A; Crowley J; Sawyer J; Morgan G; Barlogie B; van Rhee F
Clin Cancer Res; 2017 Jun; 23(11):2665-2672. PubMed ID: 27810902
[No Abstract] [Full Text] [Related]
16. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
17. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.
Barlogie B; Attal M; Crowley J; van Rhee F; Szymonifka J; Moreau P; Durie BG; Harousseau JL
J Clin Oncol; 2010 Mar; 28(7):1209-14. PubMed ID: 20085933
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
20. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]